PR Newswire·Aug 10, 2026, 8:30 AM ET

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma reported Q2 2026 financial results with YUPELRI collaboration revenue increasing 11% year-over-year to $20.7 million.
The company announced a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right, with the transaction expected to close in the second half of 2026.
Organizational restructuring reduced operating expenses by 35% year-over-year (excluding restructuring costs), with a full run-rate reduction of approximately 60% relative to 2025 expected by the second half of 2026.
GSK reported TRELEGY net sales of approximately $1.0 billion for Q2 2026, with high confidence in achieving the $100 million milestone payment from Royalty Pharma.
Quarter-end cash balance stood at $388 million with no debt outstanding.
YUPELRI U.S. net sales reached $70.7 million in Q2 2026, a 7% year-over-year increase driven by 10% growth in customer demand.
Net loss for Q2 2026 was $5.9 million compared to a net income of $54.8 million in the same period in 2025, which included a one-time $75.1 million gain from royalty asset sales.
Non-GAAP net income from operations for Q2 2026 was $9.5 million, contrasting with a non-GAAP net loss of $4.2 million in Q2 2025.
Transaction-related expenses associated with the Zymeworks acquisition totaled $6.1 million in Q2 2026.
The company will not host a conference call or webcast to discuss these quarterly results.